Advertisement


Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Advertisement